Connecticut looks to broaden psychedelic drug therapy access as Trump move boosts momentum

Connecticut legislators are moving to expand access to psychedelic-assisted therapy following President Donald Trump's executive order to accelerate reviews of certain psychedelic drugs for medical purposes. The state Senate unanimously passed legislation to open a pilot treatment program involving MDMA and psilocybin to qualifying patients aged 18 and older. The program is currently limited to Connecticut veterans, retired first responders, and direct healthcare workers. The FDA is now taking regulatory actions to carry out Trump's directive for prioritizing treatments for PTSD, treatment-resistant depression, and substance use disorders. The Senate legislation now needs to pass the state House of Representatives before the session ends May 6. Clinical researchers overseeing the program reported no serious adverse events to date.